Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
7.65    0.25 (3.38%)
Bid:
7.40
Ask:
7.90
Spread: 0.50 (6.757%)
Market Cap: £3.35m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Presentation at RSNA 2017

22 Nov 2017 07:00

RNS Number : 1585X
Feedback PLC
22 November 2017
 

Presentation at RSNA 2017

 

Cambridge, UK - 22 November 2017: Feedback plc ("Feedback" or the "Company") (AIM: FDBK), the specialist medical imaging technology company, announces that Dr Balaji Ganeshan will be presenting at the 103rd Scientific Assembly and Annual Meeting of the Radiological Society of North America ("RSNA 2017") taking place from 26 November to 1 December 2017 in Chicago (IL), USA.

 

The details for the oral presentation on the study undertaken at the Institute of Nuclear Medicine, University College London, UK are as follows:

 

Date and session time: Wednesday 29 November at 15:00 - 16:00 CST

Title: Texture Analysis of 68Ga-DOTATATE Positron Emission Tomography and Computed Tomography Images as a Prognostic Biomarker in Adults with Neuro-Endocrine Cancers Treated with 177Lu-DOTATATE

Abstract number: SSM13-06

Session: Molecular Imaging (Analysis and Quantification)

Room: S504C

Presenter: Balaji Ganeshan, PhD

 

Two additional papers co-authored by Dr Balaji Ganeshan will be presented at RSNA 2017; one by Seoul National University and University College London focused on liver cancer (abstract SSK07-05), and one by Cambridge University, the University of Rome and University College London focused on ischemic stroke (abstract SSQ15-02). Overall, RSNA 2017 is expected to include at least 18 scientific paper presentations featuring TexRAD® Computed Tomography Texture Analysis (CTTA) and Magnetic Resonance Texture Analysis (MRTA), many of which have won awards in this year's RSNA categories. Further information can be found at https://rsna2017.rsna.org/program.

 

Dr Balaji Ganeshan, Director of New Business at Feedback plc, said: "RSNA is the premier global event for radiologists and the increasing focus on our TexRAD® technology is encouraging. As seen in previous years, our renowned customers will highlight multiple TexRAD® presentations across various disease indications, further emphasising the significance of our technology across the healthcare industry. We look forward to discussing TexRAD® with this year's RSNA delegates."

 

TexRAD® is the Company's patented quantitative image texture analysis technology for diagnostic radiological scans. The technology has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer, or other disease indications, and is currently installed in over 40 of the world's leading research institutions across Europe, North America, Asia and Australasia. By analysing the texture features in computerised tomography (CT) scans, magnetic resonance images (MRI) and positron emission tomography scans (PET/CT), TexRAD®'s quantitative imaging capabilities provide clinicians with additional, visually imperceptible information to make better decisions in order to improve patient outcomes.

 

TexRAD® research to date has shown great potential in many different oncological and non-oncological sites. In particular, the papers being presented at RSNA 2017 focus on liver, pancreatic, kidney, cervical, oral, genitourinary, head & neck, thyroid, neuroendocrine and endometrial cancers, as well as gastrointestinal stromal tumours, gliomas, thymic-epithelial neoplasms and carotid-plaques. On 20 November 2017, Feedback announced the CE marked release of TexRAD® Lung, a "software only" Class 1 medical device, to help advance lung cancer diagnosis. Further information on the TexRAD® technology can be found at www.texrad.com.

 

- Ends -

 

 

Notes to editors

 

About Feedback plc

Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD®, the Company's patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world's leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data. Visit www.fbk.com.

 

For further information, please contact:

 

Feedback plc

Dr Alastair Riddell, Chairman

Lara Mott, Investor Relations

 

Tel: 01954 718072

hello@fbk.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAFMMZMNMDGNZM
Date   Source Headline
22nd Apr 20262:10 pmRNSGrant of Options and PDMR dealing
20th Apr 20267:00 amRNSNHS Progress and Business Update
17th Feb 202610:43 amRNSCorrection: Half-year Report
17th Feb 20267:00 amRNSHalf-year Report
2nd Feb 20267:00 amRNSNotice of Results & Retail Investor Presentation
5th Jan 20264:13 pmRNSHolding(s) in Company
23rd Dec 20253:44 pmRNSHolding(s) in Company
23rd Dec 20253:44 pmRNSHolding(s) in Company
23rd Dec 20253:33 pmRNSDirector/PDMR Shareholding
23rd Dec 20253:33 pmRNSDirector/PDMR Shareholding
18th Dec 20257:00 amRNSTrading Update
20th Oct 20257:00 amRNSDirectorate Change
13th Oct 20254:04 pmRNSResult of AGM
18th Sep 20251:07 pmRNSNotice of AGM
17th Sep 20257:00 amRNSFinal Results
8th Sep 20257:00 amRNSNotice of Results & Retail Investor Presentation
10th Jul 20257:00 amRNSGrant of Options and PDMR dealing
12th Jun 20257:00 amRNS-RNeighbourhood Health Service Simulation
7th May 202510:44 amRNSHolding(s) in Company
6th May 20251:01 pmRNSHolding(s) in Company
28th Apr 20257:00 amRNSTrading Update
25th Feb 20257:00 amRNSHalf-year Report
11th Feb 20257:00 amRNSNotice of Results & Investor Presentation
14th Jan 20257:00 amRNSSurrender and grant of options and PDMR dealings
18th Dec 20243:07 pmRNSHolding(s) in Company
18th Dec 20247:00 amRNSHalf Year Trading Update
9th Dec 202410:56 amRNSHolding(s) in Company
9th Dec 202410:48 amRNSHolding(s) in Company
4th Dec 20247:00 amRNSHolding(s) in Company
3rd Dec 202412:33 pmRNSHolding(s) in Company
3rd Dec 202412:18 pmRNSHolding(s) in Company
2nd Dec 202411:53 amRNSHolding(s) in Company
2nd Dec 202411:46 amRNSHolding(s) in Company
2nd Dec 20247:00 amRNSDirector/PDMR Shareholding
29th Nov 20243:36 pmRNSHolding(s) in Company
29th Nov 20243:33 pmRNSHolding(s) in Company
28th Nov 20242:35 pmRNSResult of AGM & Commercial Update
6th Nov 20247:00 amRNSResult of WRAP Retail Offer
4th Nov 20243:46 pmRNSSuccessful Fundraising upscaled to c. £5.57m
4th Nov 20247:02 amRNSWRAP Retail Offer for up to £1 million
4th Nov 20247:01 amRNSProposed Fundraise & Share Capital Reorganisation
4th Nov 20247:00 amRNSFinal Results
16th Oct 20247:00 amRNSElective Recovery Fund funding mechanism
19th Sep 20247:00 amRNSCollaboration Agreement
2nd Sep 20247:00 amRNSFurther funding to extend NHS Trust pathways
10th Jul 20247:00 amRNSVertex In Healthcare Collaboration
1st Jul 20247:00 amRNSCDC Contract Awarded by Queen Victoria Hospital
28th Jun 20247:00 amRNSChange of Name of Nominated Adviser and Broker
22nd May 20247:00 amRNSTrading Update
25th Mar 20247:00 amRNSNew tuberculosis partnership in India

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.